- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04903171
Effects of Enriched Gardens in Nursing Home Residents With Dementia
May 21, 2021 updated by: RIVAGES
Effects of Enriched Gardens on Cognition and Independence of Nursing Home Residents With Dementia: a Cluster-controlled Trial
Comparing the effect of the frequentation of an enriched garden vs sensory conventional garden by nursing home residents with Alzheimer disease.
The effects will be evaluated as regards to cognitive impairment (MMSE), autonomy (ADL) and prevention of falls (Unipodal stance and UpandGo Test)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The cluster controlled trial is conducted over a six months period after recruitment of residents from 4 different nursing homes in France.
The participants are distributed into 3 groups.
One group does not receive incentive from carers to visit any garden, the second group receives incentives to visit regularly a conventional sensory garden and the third group receive incentives from carers to visit regularly an enriched garden.
The study is conducted over a period of 6 months.
All participants are giving consent to the study.
They will be evaluated before and after over 4 different tests.
MMSE (Mini Mental Status Examination) for cognitive impairment, ADL (Activity for day Living) for functional autonomy, TUG (Test up and Go) and Unipodal Stance for prevention of falls.
Study Type
Interventional
Enrollment (Actual)
130
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Val De Marne
-
Ivry-sur-Seine, Val De Marne, France, 94200
- Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix et Sorbonne Université
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
75 years to 95 years (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Give consent
- Ability walking alone
- Alzheimer's disease
Exclusion Criteria:
- No dementia
- Severe dementia
- Severe behavioural disorder
- Inability to walk alone
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: GROUP ONE
The participants do not receive incentive to visit any gardens
|
|
|
Placebo Comparator: GROUP TWO
The participants receive incentives by carers to visit regularly a conventional sensory garden
|
Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
|
|
Experimental: GROUP THREE
The participants receive incentives by carers to visit regularly an enriched garden
|
Carers invites every the participants of group 2 and 3 visiting their respective gardens (enriched or conventional sensory garden)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in global cognitive function
Time Frame: 6 MONTHS
|
Mini Mental Status Examination (MMSE) , 0-30, higher score is the better outcome
|
6 MONTHS
|
|
Change in functional independence
Time Frame: 6 MONTHS
|
Activities of daily living (ADL), 0-6, higher score is the better outcome
|
6 MONTHS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in gait ability
Time Frame: 6 MONTHS
|
Timed Up and Go test (sec), higher time is the worse outcome
|
6 MONTHS
|
|
Change in balance
Time Frame: 6 MONTHS
|
Unipodal Stance (sec), higher time is the better outcome
|
6 MONTHS
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2020
Primary Completion (Actual)
October 15, 2020
Study Completion (Actual)
October 15, 2020
Study Registration Dates
First Submitted
March 3, 2021
First Submitted That Met QC Criteria
May 21, 2021
First Posted (Actual)
May 26, 2021
Study Record Updates
Last Update Posted (Actual)
May 26, 2021
Last Update Submitted That Met QC Criteria
May 21, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIVAGES
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
IPD will only be available to study reviewers
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeWithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Stanford UniversityNot yet recruitingMCI With Increased Risk for Alzheimer Disease | Alzheimer s DiseaseUnited States
-
University of California, Los AngelesRecruitingAlzheimer Disease | Dementia Alzheimer Type | Alzheimer&Amp;#39;s Disease (AD) | Alzheimer&Amp;Amp;#39;s Disease | Mild Alzheimer&Amp;Amp;#39;s Disease | Moderate Alzheimer&Amp;Amp;#39;s Disease | Alzheimer&Amp;#39;s DementiaUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Heinrich-Heine University, DuesseldorfNot yet recruitingEarly Onset Alzheimer Disease | Alzheimer Disease (AD)Germany
-
Johns Hopkins UniversityNational Institutes of Health (NIH)Not yet recruiting
-
Xuanwu Hospital, BeijingEnrolling by invitation
-
University Hospital, GrenobleRecruiting
-
Fujian Medical University Union HospitalRecruitingAlzheimer s DiseaseChina
Clinical Trials on INCENTIVE VISITING A GARDEN : ENRICHED OR CONVENTIONAL SENSORY GARDEN
-
UMC UtrechtNational University Hospital, Singapore; Berry Consultants; University of Pittsburgh... and other collaboratorsRecruitingCommunity-acquired Pneumonia, Influenza, COVID-19United Kingdom, United States, Canada, Australia, Netherlands, Spain, Croatia, Belgium, New Zealand, Ireland, France, Italy, Japan, Slovenia, Colombia, India, Nepal, Pakistan, Portugal, Saudi Arabia, Germany, Israel, Czechia, Estonia, F... and more